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ABSTRACT 
 
The Metabolic Syndrome (MetS) affects 35% of U.S. adults and is an indicator of 
early death. While pharmacological treatments have been developed for the majority of 
MetS risk factors, obesity-induced inflammation remains to be addressed. Dysfunctional 
adipose tissue is a source of inflammation, and perivascular adipose tissue (PVAT) is 
critical in its pathogenesis. This study investigates the effects of red raspberry (rubus 
idaeus) diet-enrichment on inflammation of PVAT. The obese Zucker rat (OZR) model 
of MetS and the lean Zucker rat (LZR) control (C) model were used. Rats received an 
eight-week control or whole red raspberry-enriched (WRR) diet (8% w/w red raspberry 
powder). RT-PCR was performed on LZR and OZR PVAT homogenates to determine 
gene expression of pro-inflammatory markers (IL-1β, IL-6, MCP- 1, NF- κB, TNF- α) 
and anti-inflammatory markers (adiponectin and IL-10), and ELISAs were performed to 
determine concentrations of a subset of these markers (adiponectin, IL-1β, IL-10, MCP-
1). RT-PCR analyses of PVAT indicated a significant down-regulation of pro-
inflammatory marker NF-κB in OZR-C versus LZR-C models. ELISA analyses indicated 
a significant increase in anti-inflammatory marker adiponectin concentration in OZR-
WRR versus OZR-C models, a significant decrease in anti-inflammatory marker IL-10 
concentration in OZR-C versus LZR-C models, and a significant decrease in pro-
inflammatory marker IL-1β concentration in OZR-C versus LZR-C models. Findings 
suggest that WRR enrichment does not have a consistent genomic or proteomic effect on 
PVAT inflammation status. Further investigations are needed to elucidate the molecular 
mechanisms dictating the pro-inflammatory and anti-inflammatory effects observed.
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INTRODUCTION 
The Metabolic Syndrome (MetS) is a collection of risk factors that affects greater 
than 30% of U.S. adults and is a significant indicator of early death (1–4). A major 
contributing factor to the dangers associated with MetS is obesity-induced inflammation 
(5). While pharmacological treatments have been developed for the majority of MetS risk 
factors, obesity-induced inflammation remains to be addressed. Considering that obesity 
rates are persistently increasing in the United States, with over two-thirds of US adults 
either overweight or obese, effective prevention and treatment are essential to improve 
and protect the well-being of citizens (4). This is particularly important in the State of 
Maine, with the highest obesity rate in New England at 29.1% (6).  
An established source of inflammation in conditions of obesity is dysfunctional 
adipose tissue (7). The role of visceral adiposity in MetS has been explored at length, 
however recent research suggests that perivascular adipose tissue (PVAT) is critical in 
the pathogenesis of dysfunctional adipose tissue. PVAT surrounds blood vessels and is a 
highly-active endocrine organ, directly influencing vascular tone and inflammation (7). 
PVAT releases several anti-inflammatory markers and has been observed to benefit 
vascular function in healthy individuals (7). However, in imbalanced states such as 
chronic obesity, PVAT can become dysfunctional and releases pro-inflammatory 
markers, yielding a loss of the benefits conferred by PVAT (7). Much remains to be 
understood about the changes that convert PVAT from a functional to a dysfunctional 
state, as well as modalities for improvement. There is a paucity of studies on whether, or 
how, diet modulates PVAT biochemistry and physiology for application to this gap in 
knowledge.  
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The few studies that have investigated the effect of diet on PVAT biochemistry 
and physiology used rodent models and high-fat diet (HFD) feeding, with some 
experiments also employing calorie restriction diets (8, 9). Resultant data have 
demonstrated effects on adipocyte (adipose cell) size and number, gene expression, and 
inflammatory marker production upon dietary changes (8, 9). There is a lack of studies on 
the effect of different diets on PVAT and inflammation status. Studies investigating the 
effects of functional foods (those which confer physiological benefits) on PVAT are also 
limited, and only a small number of these have employed berries.  
Berries are known for their robust antioxidant content (2). Red raspberries are 
gaining nutritional interest due to their unique bioactive profiles, with a particularly high 
level of the polyphenol ellagitannin which has been documented to physiologically 
benefit cardiovascular health (10). Previous studies in the Klimis-Zacas laboratory have 
demonstrated the efficacy of a wild blueberry-enriched diet in the attenuation of obesity-
induced inflammation, through successfully decreasing PVAT expression and 
concentration of inflammatory markers in the obese Zucker rat (OZR), a model of MetS 
(11–14).  
This study aims to address the gap in knowledge regarding the effect of a red 
raspberry-enriched diet on PVAT and inflammation status. The specific goal of this study 
is to determine gene expression of the pro-inflammatory markers IL-1β, IL-6, MCP- 1, 
NF- κB, and TNF- α and the anti-inflammatory markers adiponectin and IL-10, and to 
determine concentrations of a subset of these markers (adiponectin, IL-1β, IL-10, and 
MCP-1) in the PVAT of two obese Zucker rat (OZR) and two lean Zucker rat (LZR) 
groups: those receiving a control diet and those receiving a red raspberry-enriched diet.  
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LITERATURE REVIEW 
 
I. Metabolic Syndrome 
The Metabolic Syndrome (MetS) is a collection of risk factors, including 
abdominal obesity, insulin resistance, dyslipidemia, elevated blood pressure, and 
decreased HDL cholesterol (1, 2). It is important to note that slightly varying definitions 
for MetS do exist among different health organizations, including the use of weight 
circumference versus body mass index, and varying triglyceride and blood pressure 
definitions (1). The definition used in this study is established by the US National 
Cholesterol Education Program- Adult Panel III (NCEP ATPIII) (2, 15). 
 MetS is generally diagnosed when at least three of these five risk factors are 
present (16). MetS affects greater than 30% of U.S. adults and is a significant indicator of 
early death (3, 4). There are established connections between MetS and elevated risk for 
several diseases, including Cardiovascular Disease, Diabetes Mellitus, esophageal and 
liver cancer, and schizophrenia (17–19). Other conditions which are often observed as 
comorbidities with MetS are a pro-thrombotic and/or pro-inflammatory state, non-
alcoholic fatty liver disease, and reproductive disorders (1). Therefore, MetS is relevant 
to a variety of fields of study and medical practice. 
Current MetS treatment options primarily involve lifestyle interventions, such as 
physical fitness, dietary changes, smoking cessation, and stress reduction (20). 
Medications can also be employed to target certain MetS conditions, including ACE 
inhibitors for high blood pressure, statins to regulate cholesterol, and low-dose aspirin for 
heart attack and stroke risk reduction (20). A study conducted by The Diabetes 
Prevention Program compared outcomes for patients following lifestyle interventions 
 
4 
 
(weight loss using diet and exercise) versus metformin, a medication for high blood 
sugar, and versus a placebo treatment (21). The initial screening step of the study was the 
presence of impaired glucose tolerance in subjects, followed by measurements of blood 
pressure, waist circumference, and fasting HDL and triglyceride levels (21). The study 
documented that when compared with placebo results, MetS incidence was reduced by 
41% for patients employing lifestyle changes, while it was reduced by only 17% for the 
metformin-receiving patients (21). Following a three-year period, MetS was “resolved” in 
38% of the lifestyle-changes group, 23% of the metformin group, and 18% of the placebo 
group (21). Certain diets have been documented to be particularly effective in the 
improvement of various MetS risk-factors and comorbidities, including calorie-restricted 
diets for obesity, diabetes, inflammation, and cardiovascular disease (CVD), increased 
meal frequency for obesity, and the Mediterranean Diet for diabetes, CVD and obesity 
(22). 
 
II. Obesity-Induced Inflammation 
As mentioned previously, a pro-inflammatory state is recognized as a co-
morbidity of MetS (1). Inflammation is a tissue response to stimuli such as injury, 
pathogens, stress, and the presence of other irritants (23). The acute inflammatory 
response includes dead or infected cell removal, tissue repair, and wound healing (23). 
Specifically, the acute inflammatory response is initiated by resident macrophages and 
mast cells, which produce inflammatory mediators including chemokines and cytokines 
(24). This triggers leukocyte delivery to the site of injury, among other “plasma 
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components,” which then leads to production of inflammatory mediators such as 
chemokines and cytokines (24).  
This cascade of events enables the “injurious agent” to be removed, followed by 
the presence of anti-inflammatory and pro-resolution cytokines, and the activity of 
macrophages (24). These macrophages include both those which are residents to the 
tissue of interest and those which have been newly-recruited (24). Resolution of 
inflammation then involves apoptosis and phagocytosis of leukocytes by macrophages, 
and subsequent departure from the site of inflammation via lymphatic drainage (24). 
These events all support the transition back to a healthy state of homeostasis in the tissue 
(24). 
Acute inflammation is an essential component in the successful resolution of 
injuries (24). However, it is when the inflammatory state is either not resolved or is 
dysregulated, and becomes chronic, that it can become harmful to the body (24). Failure 
to resolve the inflammatory state can occur when the original stimuli are not neutralized 
and removed, or if they are removed but inflammatory cells and molecules remain in and 
near to the site of injury (24). In cases of obesity, excessive adipose tissue expansion 
leads to some adipocytes becoming apoptotic, which prompts subsequent recruitment of 
pro-inflammatory macrophages (25, 26). Macrophages are a diverse and adaptable family 
of large cells with roles in detection and phagocytosis of foreign material, antigen 
presentation, and the release of cytokines for inflammation initiation (27, 28). Due to 
their adaptability among phenotypes, macrophages are both very important for healthy 
repair and maintenance of homeostasis, and capable of contributing to the development 
of chronic inflammatory diseases (28). 
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In the case of adipose tissue inflammation, macrophage infiltration leads to an 
elevated production of pro-inflammatory cytokines (29). Research has demonstrated that 
inflammatory cytokine expression in adipose tissue is primarily sourced from 
macrophages, not from adipocytes, which suggests that inflammation is initiated at least 
in part by macrophage infiltration (29). One theory states that initiation of macrophage 
infiltration is caused by adipose tissue expansion occurring in concert with weight gain, 
and the subsequent cascade of events that this causes (29). These events include death of 
adipocytes, elevated leptin secretion, and recruitment of neutrophils and T cells (29). 
Upon adipose tissue macrophage infiltration, these macrophages then recruit more 
macrophages through the release of chemokines such as MCP-1 (29). The subsequent 
abundance of macrophages can contribute to adipose tissue remodeling, in which the 
shape and number of adipocytes change (29). 
A possible result of this cascade of events is the polarization of macrophages to 
either an M1 or an M2 macrophage phenotype (29). The M1 macrophage phenotype is 
referred to as “classically-activated,” with inflammation prompting its formation, while 
the M2 macrophage phenotype is prompted by IL-4 and IL-13 exposure (29). 
Macrophages with an M1 phenotype secrete pro-inflammatory cytokines, while 
macrophages with an M2 phenotype secrete anti-inflammatory cytokines and potentially 
assist in tissue repair (29). Research has indicated that lean mice possess adipose tissue 
with higher levels of M2 macrophages, and mice receiving a high-fat diet possess higher 
levels of M1 macrophages (29, 30). Human studies have confirmed the presence of both 
M1 and M2 populations in adipose tissue, and that these populations secrete pro- and 
anti-inflammatory cytokines in the same pattern that mice do (29, 31). Further, it has 
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been reported that M1 adipose tissue macrophages are major causes of both adipose 
tissue inflammation and insulin resistance in obesity (32). 
 
III. Model for Obesity-Induced Inflammation 
The obese Zucker rat (OZR) is a model of Human MetS, while the lean Zucker rat 
(LZR) is a control model (33, 34). OZRs are an effective model for human MetS because 
they exhibit all of the risk factors associated with MetS (33, 34). Compared with LZRs, 
OZRs exhibit hyperphagia, elevated circulating insulin levels, hyperlipidemia and 
elevated inflammation (33). The OZR genotype, fa/fa, causes a leptin receptor defect, and 
subsequent development of hypertriglyceridemia, hypercholesterolemia, 
hyperinsulinemia, and insulin resistance, and “moderate” hypertension which develops 
between eight and twenty weeks of age (13). OZRs become obese within three-to-five 
weeks of age (33). Only male rats were used in the present study; previous experiments in 
different studies have indicated that female rats can influence results due to hormonal 
conditions (35). 
The leptin receptor mutation characteristic of the fa/fa genotype causes leptin 
signaling to be impaired, which is a contributing factor to the higher body weight of OZR 
(33, 36). This is because leptin plays a significant role in the regulation of energy balance 
(33, 36). Leptin is a protein produced and released by adipose tissue, with release 
occurring at a rate that is proportional to the quantity of lipids stored (33). Leptin targets 
leptin receptors in the brain, with elevated targeting associated with decreased food 
intake and elevated energy expenditure (33). The levels of circulating leptin are 
significantly elevated in OZR compared with LZR (33). 
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IV. Inflammatory Markers 
Adiponectin 
 Adiponectin (also known as Acrp30, adipo-Q, and apM1) is a cytokine produced 
by adipose tissue, also known as an adipokine (37). Adiponectin was first discovered in 
1995, and has since emerged as a molecule with prominent roles in the initiation and 
alteration of metabolic responses and inflammation, as well as cardio-protection (37, 38). 
Adiponectin is primarily known as an anti-inflammatory cytokine; circulating plasma 
levels of adiponectin are typically elevated in healthy individuals compared with in cases 
of obesity, in which circulating levels decrease (39). Adiponectin can be secreted by 
PVAT, and has been observed to normalize endothelial function through a subsequent 
elevation in eNOS phosphorylation, and suppression of ROS generation as a negative 
modulator of innate immune response (39, 40). The protective effects of adiponectin may 
also be due to its regulation of energy substrate and calcium ion metabolism (38).  
In studies using lean mice, the adiponectin produced by PVAT has been 
established to exert anti-inflammatory effects that attenuate neointimal formation (41, 
42). The neointima is the arterial intima layer that thickens in cases of atherosclerosis, 
through cell migration and proliferation (43). In addition, adiponectin has been shown to 
modulate macrophage function towards an anti-inflammatory phenotype, through 
polarization towards the M2 phenotype, supporting the classification of adiponectin as an 
anti-inflammatory cytokine (39) (44). 
 Adiponectin is unique in its proposed role in a compensatory mechanism of action 
in cases of inflammation (45–47).  This compensatory mechanism has been suspected 
due to evidence of elevated adiponectin expression and concentration in certain cases of 
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inflammation (45–47). In a study of humans with a BMI less than 25, between 25 and 30, 
or greater than 30, the left internal thoracic artery PVAT of patients in the highest BMI 
category had significantly elevated adiponectin compared with those in the other two 
categories (47). In that study the patients with a BMI greater than 30 also exhibited a 
slightly improved endothelium-dependent vascular function compared with patients with 
a BMI between 25 and 30 (47). These findings support the proposed compensatory 
mechanism, with the potential for the elevated adiponectin expression to have improved 
the vascular function of those in the highest BMI category. However, it is unclear what 
exact conditions prompt such a response, as well as the duration of time that this response 
persists. 
 
IL-10 
 IL-10 (also known as CSIF or TGIF) is an anti-inflammatory cytokine produced 
primarily by macrophages with M2 polarization (39, 48). The roles of IL-10 include 
inhibition of macrophage, Th1, and NK cell activity at times of infection, as well as 
inhibition of pro-inflammatory cytokine synthesis (48, 49). IL-10 also inhibits NADPH-
dependent oxidative stress and elevates NO production, which improves endothelial 
function (39). While this cytokine is important for a healthy inflammatory response and 
clearance of pathogens, it can also cause tissue damage when present in excess; therefore, 
the action of IL-10 must be tightly-regulated to maintain a healthy infection response 
(48).  
With regards to MetS, low circulating IL-10 levels have been associated with 
MetS, as well as with high body mass index and high percent fat mass (50). IL-10 has 
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also been shown to exert protection against the formation and stability of atherosclerotic 
lesions (49). In a study that investigated IL-10 levels in obese and non-obese women with 
MetS, both populations were determined to have elevated circulating IL-10 levels (49). 
This finding suggests that in cases of MetS the body responds by elevating IL-10 levels, 
in an attempt to inhibit the elevated pro-inflammatory cytokine production that has 
developed (49). In the same study, following a 12-month lifestyle program that included 
elevated physical activity, obese women without MetS exhibited a decrease in circulating 
IL-10 levels; however, this decrease was not observed among obese women with MetS 
(49).  
Of note, the STAT3 gene is a downstream target of IL-10 (51). The Janus 
kinase/signal transducers and activators of transcription (JAK-STAT) pathway is 
associated with preventing the development of obesity-associated disorders such as leptin 
resistance and insulin resistance, and the STAT3 gene is a downstream target of IL-10 
(51). The JAK-STAT pathway is key in the development of many inflammation-related 
diseases such as obesity and cancer, and specifically can contribute to pathogenesis in 
cases of chronic activation (52). JAK-STAT is also involved in the regulation of many 
“developmental and homeostatic processes” by molecules such as cytokines and 
hormones (52). 
While no studies have been identified that investigate the gene expression or 
protein concentration of IL-10 in PVAT, some studies have elucidated connections 
between brown adipose tissue (BAT) thermogenesis and IL-10 (53). An unexpected 
finding determined that removal of IL-10 signaling in mice actually caused WAT 
browning, as well as conferred protection against diet-induced obesity, with elevated 
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mitochondrial respiration observed (53). The study employed an antisense 
oligonucleotide WAT IL-10 receptor knock-down. Research conducted by the same lab 
indicates that IL-10 is a repressor of thermogenic gene transcription, through chromatin 
modulations at “key enhancer and promoter regions” (53). This research used a genome-
wide Assay for Transposase-Accessible Chromatin (ATAC)-seq and RNA-seq, and the 
findings suggest that IL-10 is a “novel regulator of a thermogenic transcriptional program 
in adipose tissue” (53). 
 
IL-1β 
 IL-1β is a pleiotropic pro-inflammatory cytokine with roles in sleep, hunger, 
injury response and inflammation (54). IL-1β is important for protection during 
infections, however, similar to other inflammatory cytokines, overly elevated expression 
of IL-1β can cause tissue damage (55). This molecule is produced primarily by 
macrophages but is also released by dendritic cells (39). Dendritic cells are most often 
present on the border between PVAT and the adventitia, but they can also exist within 
PVAT (39). IL-1β is believed to play a role in the development of insulin resistance in 
cases of obesity (56). Specifically, it has been observed that IL-1β acts through the 
inhibition of insulin signaling (56, 57). Furthermore, it has been determined that insulin 
signaling and action in human adipocytes is improved upon blocking IL-1β activity (56, 
58, 59). High levels of circulating levels of IL-1B, in concert with high circulating levels 
of IL-6, have been determined as a prediction for Type 2 Diabetes (60).  
White adipose tissue (WAT) has generally been observed to release an elevated 
amount of IL-1β in cases of human and rodent obesity, with expression higher in visceral 
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than subcutaneous adipose tissue (57, 60, 61). Previous in vivo and in vitro adipocyte 
studies have indicated that IL-1β plays roles in lipolysis activation, insulin resistance, and 
adipogenesis inhibition in adipose tissue, as well as elevated expression and secretion in 
cases of inflammation (60, 62–64). It has also been observed that “lipid storage capacity” 
in adipose tissue, adipose tissue macrophages, and the liver can be regulated by IL-1β 
(60). Interestingly, due to the adipogenesis-inhibiting action and adipose tissue-liver 
crosstalk abilities of IL-1β, low levels of this cytokine are associated with lower liver 
weights in cases of excess calorie consumption (60).  
IL-1β is unique among cytokines in that it is not initially inactive upon being 
produced, and in order to become biologically active must first be activated by 
inflammasomes via cleaving by caspase-1 (55, 56). Inflammasomes are protein 
complexes of several subunits that regulate caspase-1 (formerly called IL-1 beta 
converting enzyme/ICE), which is a proteolytic enzyme (65). Inflammasomes also 
typically contain nucleotide-binding domain–like receptors (NLRs), and stimuli that can 
activate NLRs include mitochondrial ROS, bacterial flagellin, extracellular ATP, 
potassium efflux, and components of the type III secretion system, among other signals 
(55, 66, 67). It has been determined that the production of IL-1β by macrophages requires 
the inflammasome components NLRP3, ASC and caspase-1, but not NLRC4, in cases of 
infection (55). Due to the ability of IL-1β to cause tissue damage in cases of 
overexpression, it is believed that abnormalities in inflammasome regulation and 
activation are involved in inflammatory disease pathogenesis (55).  
Studies investigating IL-1β expression and content in PVAT are limited, however 
two studies have been identified (68, 69). One study that investigated human patients 
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with coronary heart disease documented that IL-1β was expressed at significantly higher 
levels in coronary artery PVAT (PVAT-CA) vs. internal thoracic artery PVAT (PVAT-
ITA) (68). This finding aligns with a previous understanding that PVAT-ITA exhibits 
atherosclerosis resistance, and therefore it is often used as an artery bypass graft, due to 
the nature of IL-1β as a pro-inflammatory cytokine (68). These results also provide 
further evidence for the previously discussed understanding that varying adipose tissue 
depots exhibit varying phenotypes and functions. In a different study that investigated 
cultured visceral perivascular adipocytes isolated from human smokers and non-smokers, 
the perivascular adipocytes of those who smoked regularly exhibited elevated P2X7R-
inflammasome complex expression and activity (69). This suggests that regular smoking 
elevates PVAT inflammatory status, which aligns with previously held findings that 
smoking is a risk factor for cardiovascular disease (70). 
 
IL-6 
 IL-6 is a pluripotent pro-inflammatory cytokine and marker of M1 polarization 
that regulates body weight and lipid metabolism at a systemic level (71). It is suspected 
that IL-6 secretion is regulated by a diverse array of factors, including hormones, 
cytokines, diet, physical activity, stress, and hypoxia (72). Higher circulating plasma and 
adipose tissue concentrations of IL-6 are associated with chronic obesity and insulin 
resistance (73). Despite this association, both beneficial and harmful effects of IL-6 have 
been observed with regard to each of these conditions, and the many roles of IL-6 
continue to be elucidated (71). It is interesting to note that insulin resistance is more 
closely linked to adipose tissue concentrations and secretions of IL-6 than with 
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circulating plasma IL-6 levels (73). It is also interesting to consider that anorexia nervosa 
has been associated with elevated systemic IL-6 levels (73). It is suspected that IL-6 
levels are elevated secondary to extreme calorie deficits, however they may also have a 
role in the cachexia of anorexia due to a similar role in cancer-associated cachexia (74). 
Secretion of IL-6 has been documented from macrophages, adipocytes, skeletal 
muscle, fibroblasts, and endothelial cells (71). This cytokine is generally present in 
higher expression levels in human abdominal versus subcutaneous adipose tissue, and in 
much higher levels surrounding adipose tissue than in circulating plasma (75). It is 
suspected that IL-6 may play a role in the control of adipose tissue mitochondrial content, 
through the activation of AMPK and subsequent regulation of PGC-1a and mitochondrial 
biogenesis (75). IL-6 has also been documented to decrease lipoprotein lipase (LPL) 
activity in humans, thus potentially affecting adipocyte metabolism (73). 
Few studies have been conducted regarding IL-6 presence in PVAT. In a study 
using cell-cultured aortic PVAT from low-density lipoprotein receptor-deficient mice, it 
was determined that elevated secretion of PVAT-derived IL-6 mediated aortic stiffening 
and remodeling (76). It has also been observed that IL-6 inhibition attenuates mechanical 
stiffness (76). Based upon other studies it is also understood that IL-6 secretions are 
elevated in PVAT of older mice and from PVAT compared to other adipose tissue 
depots, and that PVAT IL-6 expression is elevated in cases of higher plasma cholesterol 
(76, 77). In addition, it has been determined that vascular smooth muscle cells (VSMCs) 
are also a source of IL-6; considering the close proximity of PVAT to VSMCs, this 
production is capable of significantly influencing PVAT inflammatory status (78).   
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MCP-1 
MCP-1 is a chemokine with key roles in the regulation of macrophage migration 
and infiltration (79). MCP-1 production is both constitutive and induced by various 
cellular stimuli, including oxidative stress and the presence of cytokines or growth factors 
(79). MCP-1 is primarily sourced from macrophages, however fibroblasts and endothelial 
cells, epithelial, smooth muscle, mesangial and astrocytic are also capable of MCP-1 
production (79). The primary functions of MCP-1 are the regulation of monocyte, natural 
killer cell, and memory T lymphocyte migration and infiltration (79).  
With regards to MetS, MCP-1 has been associated with early atherogenesis, and is 
a recognized marker of endothelial dysfunction (80). In cases of obesity, MCP-1 
expression is generally higher in visceral and subcutaneous adipose tissues of obese 
patients versus lean controls, as well as plasma concentrations of MCP-1 (81–83). 
Interestingly, fructose consumption has been documented to increase the already-high 
levels of plasma MCP-1 in obese patients (81, 84). It has also been determined that MCP-
1 plays a key role in the promotion of adipose tissue angiogenesis and development of 
obesity; in mice with an MCP-1 receptor (CCR2) deficiency, fat deposition and insulin 
resistance were reduced (81, 85).  
A limited number of studies have aimed to target MCP-1 for reduction and 
subsequent attenuation of obesity-associated syndromes (81, 86–90). In a study in which 
human MetS patients engaged in an exercise program, a decrease in plasma MCP-1 levels 
was observed (81, 88). Different studies determined that human bypass surgery resulted 
in decreased MCP-1 white adipose tissue (WAT) concentration, and administration of 
Atorvastatin (a type 2 statin) caused decreased serum MCP-1 content (81, 86, 87). Lastly, 
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using human cell culture, the administration of procyanidins from grape seeds resulted in 
decreased MCP-1 concentration, and administration of the vasodilator Dilazep caused 
elevated MCP-1 mRNA expression (81, 89, 90). 
A limited number of studies have also investigated the presence of MCP-1 in 
PVAT (11, 91, 92). In a study conducted in the Klimis-Zacas lab, the PVAT of OZRs that 
received wild blueberry enrichment had significantly lower MCP-1 concentrations when 
compared to OZRs that consumed a control diet (11). In that study the MCP-1 
concentrations of LZRs that consumed a control diet were also significantly lower than 
OZRs that consumed a control diet (11). In a study that employed artery injury and 
subsequent thoracic PVAT implantation, MCP-1 increased rates of neointima formation, 
but in the same study macrophage infiltration was unexpectedly not influenced by MCP-1 
(91). It has also been documented that dysfunctional PVAT adipocytes can cause 
elevated production of MCP-1 in PVAT (91, 92). Therefore, it follows that the presence 
of pathological conditions in PVAT, such as pro-atherosclerotic factors, has been 
associated with elevated MCP-1 concentration in PVAT (92). Inflammation of PVAT has 
also been associated with significant increases in MCP-1 PVAT concentration, while 
endovascular injury has been observed to result in significant MCP-1 upregulation in 
PVAT (92, 93).  
 
NF-κB 
 Nuclear factor kappa light chain enhancer of activated B cells (NF-κB) is a 
complex of transcription factors that have roles in the regulation of inflammation, 
immune responses, oncogenesis, metabolic diseases, and energy homeostasis (94). The 
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influence of NF-κB on the states of metabolism and inflammation are suspected to be due 
to the co-evolution and interdependence of nutrient and pathogen monitoring (94). This is 
in part because it is essential that the energy output required by organisms to defend 
against pathogens and other foreign materials not disrupt metabolic homeostasis, which 
could cause starvation (94). NF-κB consists of five subunits: NF-κB 1 (p50), Nf-κB 2 
(p52), RelA (p65), RelB, and c-Rel (95). It is the dimerization of these subunits that 
forms NF-κB (95). Twelve unique combinations of these subunits have been observed in-
vivo, and NF-κB is capable of target gene activation following assembly of its individual 
subunits (96). 
Regulation of NF-κB takes place through localization, using IκBα (97, 98). IκBα 
is an inhibitor protein that causes NF-κB dimers to remain in the cytoplasm through non-
covalent bonding (97, 98). However, upon the introduction of a diverse range of cellular 
stimuli, I kappa B kinase (IκK) is activated and subsequently degrades the IκBα that is 
complexed with NF-κB in the cytoplasm (97, 98). This degradation process begins with 
the phosphorylation of two N-terminal IκBα serines in the regulatory region, which 
prompts recognition by the ubiquitin ligase complex (97). The IκB is then 
polyubiquitinated, which serves as a signal for proteasomal degradation (97). The NF-κB 
dimers that remain are then able to translocate and accumulate in the nucleus where they 
then target genes for activation of transcription (97). This allows for activation of genes 
possessing a κB-binding site, which is a DNA-binding motif that the NF-κB dimers can 
bind to (97). 
The activation of the IκK complex is influenced in part by the presence of several 
inflammatory cytokine receptors, including IL-1β, IL-10 and TNF-α (94). Further, the 
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presence of NF-κB in the nucleus regulates expression of these same inflammatory 
cytokines (94). Therefore, these inflammatory cytokines are part of a positive-feedback 
loop of expression (94). Interestingly, in the presence of chronic overnutrition such as 
obesity, activation of NF-κB by IκK takes place in macrophages, adipocytes, and 
hepatocytes (94). This results in recruitment and activation of macrophages, which is a 
key step in the “initiation and maintenance of an inflammatory reaction” (94). 
The NF-κB pathway appears to also play a significant role in appetite regulation 
and food intake (94, 99). In studies using mice, a high-fat diet has been observed to cause 
ER stress and subsequent IKKB/NF-κB activation (94, 100). Inflammation in the 
mediobasal hypothalamus then occurs, which can lead to insulin and leptin resistance, as 
well as central leptin signaling disruptions (94, 99, 101). Central leptin signaling is 
responsible for communicating states of overnutrition to the central nervous system; 
therefore, the disruption in central leptin signaling that occurs following high-fat diet 
consumption can actually cause an elevated calorie intake, and subsequent weight gain 
(94). NF-κB also has roles in energy sensing and energy production, which are still in the 
process of elucidation (94, 102). Due to this connection between the NF-κB pathway and 
leptin signaling, it is important to note again the use of an experimental (obese) animal 
model in the current study that possesses a leptin receptor mutation (fa/fa) (34).  
The specific subunit investigated in this study is NF-κB-1 (p50). P50 is one 
component of the primary form of NF-κB, which also includes p65 (103). P50 and p65 
are named for their molecular mass, with p50 being 50 kD and p65 being 65 kD in mass 
(103). In addition to pairing with p65, p50 is also capable of binding DNA as a 
homodimer, and in both cases has a specificity for κB-binding sites (103). Previous 
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studies have indicated conflicting roles for p50 in inflammation and energy homeostasis; 
some studies using mice with a p50 deletion have observed elevated rates of exercise 
endurance and resistance to obesity, as well as the repression of obesity-associated 
symptoms such as macrophage adipose tissue infiltration and elevated blood glucose 
(104). However, other studies have observed an elevated presence of inflammatory 
cytokines (including TNF-α and IL-6) in adipose tissue and serum, and elevated 
macrophage adipose tissue infiltration, in cases of p50 knockout mice (105). Therefore, 
further studies are necessary to elucidate the specific role of p50 in inflammatory control.  
 
TNF- α 
TNF- α is a pro-inflammatory cytokine produced primarily by macrophages, but 
also by adipocytes, endothelial cells, microglia, and astroglia (106). TNF-α has been 
observed to regulate a diversity of processes including cell proliferation, survival, 
differentiation, and apoptosis (106). Abnormalities in TNF-α production have been 
associated with the pathogenesis of several inflammatory diseases, including obesity, 
diabetes and atherosclerosis (106). This finding has led to the development and approval 
of several “anti-TNF-α” drugs for disease treatment, such as those for rheumatoid 
arthritis and inflammatory bowel disease (106). Regulation of TNF-α at the 
transcriptional level by NF-κB and nuclear factor activated T cells has been documented, 
as well as at the translational level by the 3′ untranslated region (UTR) of TNF-α mRNA 
(106, 107).  
In cases of obesity, TNF-α has been documented to be secreted at levels that are 
proportional to degree of adiposity, with levels decreasing as weight is lost (108, 109). 
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Elevations in TNF-α have been documented to decrease food intake and regulate energy 
metabolism, and dysregulated TNF-α expression has been associated with obesity (110). 
In the same study that employed both cell culture and animal models, it was observed that 
TNF-α affects the release of leptin from adipose tissue, and the expression of leptin 
through post-translational regulation (110). 
 
V. Types of Adipose Tissue 
Previously viewed as simply a "passive storage organ," recent findings have 
revealed that adipose tissue has a diversity of functions, including energy production, 
organ protection, inflammation regulation, and communication with other organs through 
adipokine secretion (111). Adipose tissue is now “recognized as the body's largest 
endocrine organ,” with significant roles in both metabolism and immunity (26). From a 
basic biological perspective, adipose tissue is composed of spherical fat-containing cells, 
with fatty acid transport to and from adipose tissue facilitated by the cardiovascular 
system (112). Adipose tissue also contains cells beyond adipocytes, including precursors 
of adipocytes, endothelial cells, blood vessels, fibroblasts, leukocytes, and the stromal 
vascular fraction of stem cells (25). Specific adipose tissue components vary depending 
upon depot location, phenotype, and health of the individual (113).  
White Adipose Tissue 
White adipose tissue (WAT) is composed of unilocular, spherical lipid droplets 
and a small number of mitochondria (114). WAT plays the primary roles of energy 
storage and hormone secretion, storing energy as triacylglycerol and releasing it via free 
fatty acids and glycerol (115). An excessive accumulation of WAT has been associated 
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with an elevated risk for obesity-related disorders, as well as various metabolic diseases 
(114) (116). This is particularly true when the WAT accumulation takes place as visceral 
abdominal adipose tissue, and even more so when this tissue becomes dysfunctional 
(116). However, it is important to note that WAT does play an important role in the 
maintenance of healthy human homeostasis; in patients with familial partial 
lipodystrophy, a disease that causes progressive subcutaneous adipose tissue loss, 
metabolic complications such as hypertension and severe insulin resistance arise over 
time, and this correlation has been supported in murine studies (116, 117). 
Brown Adipose Tissue 
Brown adipose tissue (BAT) is composed of several small, polygonal vacuoles, 
and has a higher density of mitochondria and capillaries than WAT (114). BAT has the 
function of non-shivering thermogenesis, in which its ATP-generating mitochondrial 
activity is harnessed (114). BAT is abundant in newborns, as well as hibernating animals, 
due to its heat generation capabilities which support maintenance of a healthy body 
temperature. The presence of BAT is generally elevated with cold exposure, and 
decreases with age and BMI (118). Although the amount of BAT generally decreases 
with age, certain BAT depots are maintained and primarily concentrated in the cervical-
supraclavicular region (118).  
The dissipation of heat by BAT occurs via oxidation of glucose and lipids, with 
the higher number of capillaries within BAT providing higher oxygen and nutrient levels 
than WAT receives (115). Another unique aspect of BAT is its expression of uncoupling 
protein 1 (UCP-1, also known as thermogenin), which is an inner-membrane 
mitochondrial protein (115). UCP-1 plays a role in the “uncoupling of fuel oxidation 
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from ATP synthesis” (119). Heat is generated via uncoupled respiration (120). 
Specifically, UCP-1 causes a “proton leak” to occur across the mitochondrial inner 
membrane. This is an alternative cascade route that uses the mitochondrial 
electrochemical gradient for heat production rather than ATP production (121). This 
enables heat dissipation from the energy that was stored in the proton gradient (122). 
Beige Adipose Tissue 
A third adipose tissue phenotype has been observed, referred to as beige (also 
called brown-in-white, or BRITE). Beige adipose tissue exhibits characteristics of both 
WAT and BAT, with a combination of large spherical and small multilocular lipid 
droplets, higher mitochondrial concentrations than WAT, and UCP-1 expression (115). 
The presence of beige adipose tissue has been connected to resistance to obesity and 
related metabolic diseases (115). WAT can transition into beige adipose tissue following 
chronic exposure to cold temperatures, exercise, and the administration of browning 
agents, including certain foods and drugs (123). The transition from BAT to WAT is 
acknowledged as a normal component of human development, while it is the unique 
browning of WAT that forms beige adipose tissue (124). 
Perivascular Adipose Tissue 
Perivascular adipose tissue (PVAT) surrounds blood vessels and is a highly-active 
endocrine organ, directly influencing vascular tone and inflammation through its release 
of anti-and pro-inflammatory and vasoactive molecules (7, 125). PVAT is characterized 
as beige or BAT, depending upon its depot location, which has been associated with 
several beneficial effects (Figure 1) (125). PVAT has been observed to benefit vascular 
function in healthy individuals, conferring structural support and enabling the 
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maintenance of vascular homeostasis through a balanced release of anti- and pro-
inflammatory markers (7, 36, 124). This benefit has been observed to persist in 
conditions of “early obesity,” in which a putative compensatory mechanism exerts 
beneficial effects (124). The specific methods of PVAT resistance to inflammation that 
have been observed are attributed in part to an elevation in NO production (124).  
Biomechanical property studies have revealed an anti-contractile effect of PVAT 
upon surrounding arteries in healthy individuals (14). This anti-contractile effect is 
important for the regulation of vascular tone, and is mediated by the ROS that are 
generated from mitochondrial metabolism (126). Mitochondrial dysfunction has been 
observed in the adipose tissue of obese patients, leading to an elevated pro-oxidative 
status, and affecting tissue homeostasis (126). Endothelial dysfunction has been linked to 
an imbalance between vasoconstrictor and vasodilator responses, which can “impair” 
vascular tone and lead to atherosclerosis development (14). In OZR animals it has been 
observed that aortic vessels respond with an excessive endothelium-dependent 
vasodilator response, but a reduced vasoconstrictor response, compared with LZR 
animals (127–129). 
Similarly, although PVAT is associated with benefits in healthy conditions, in 
cases of chronic obesity PVAT has been observed to become dysfunctional and release 
pro-inflammatory markers, yielding a loss of the benefits conferred by PVAT (7). In the 
case of chronic obesity PVAT also exhibits a loss of anticontractile properties, which can 
contribute to vascular disease (7). This loss of anticontractile effect has been observed in 
both animal and human cases of obesity (130). However, it is important to again note that 
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in early cases of obesity-induced inflammation PVAT has been documented to exert a 
compensatory mechanism of action to maintain homeostasis (124). 
PVAT is similar to classical adipose tissue in that it contains not only adipocytes, 
but also nerves, stem cells, microvasculature, and immune cells (120). However PVAT is 
unique when compared with other adipose tissue depots is its "secretory profile” (124, 
131, 132). In murine studies, aortic PVAT has been observed to express lower levels of 
adipocyte-related genes such as PPARγ, FABP4, fatty acid synthase (FAS), lipoprotein 
lipase (LPL), and perilipin, and to produce lower levels of adiponectin and leptin, when 
compared to subcutaneous (SAT) and visceral adipose tissues VAT (124, 131, 132). 
Another distinction between PVAT and other adipose depots, such as SAT and VAT, is 
its modulated "adipocyte differentiation and maturation" marker expression (124). 
Specifically, expression of these genes is decreased in PVAT, including lipoprotein 
lipase, glycerol-3-phosphate dehydrogenase (GPDH), and perilipin (124). In a human 
adipocyte culture study, radial artery PVAT exhibited a unique "secretion pattern" when 
compared with SAT and VAT. This radial artery PVAT exhibited an elevated production 
and concentration of cytokines and factors of angiogenesis factors and cytokines, 
including MCP-1, hepatocyte growth factor (HGF), vascular endothelial growth factor, 
and thrombospondin (124). 
 The morphology of PVAT varies depending upon its anatomical location (Figure 
1) (125). Thoracic PVAT is most similar to BAT, based upon “full genome DNA 
microarray,” immunohistochemical and electron microscopy analyses of phenotype 
(131). PVAT also varies from beige adipose tissue in that it maintains this BAT 
phenotype even "in the absence of activating stimuli,” and also that it does not exhibit 
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whitening in the presence of a high-fat diet (125). This is contrasted with abdominal 
aortic PVAT which aligns more with the morphology of WAT, due to its unilocular 
adipocyte formation and low expression of UCP-1 (125). Another way in which thoracic 
PVAT is similar to BAT is in its contribution to "intravascular temperature during cold 
exposure,” through mechanisms described above (125). Further, the location of thoracic 
PVAT is close to the heart, and surrounds the thoracic artery which all blood flows 
through prior to passing to the rest of the body (133). This suggests that thoracic PVAT is 
in a region that is highly important for maintaining healthy homeostasis and function. 
 
 
Figure 1: Adipose tissue characterization varies depending upon anatomical location  
(125) 
 
 The Framingham Heart Study recently reported that high levels of thoracic PVAT 
are significantly associated with a higher prevalence of cardiovascular diseases, even in 
individuals without high levels of visceral adipose tissue (126, 134). The differential 
inflammatory status of PVAT has been identified in recent years as playing a role in the 
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prevention, or development, of diseases such as atherosclerosis (126). In the case of 
atherosclerosis, a previously-held belief was grounded in the “inside-out” theory, in 
which immune cells are delivered to the endothelium via the vasculature in cases of 
intimal injury, producing inflammation that then spreads out to the media and adventitia 
regions of the artery wall (9, 135, 136). However, recent findings elucidating the role of 
PVAT have provided evidence for a newer “outside-in” theory (9). This theory states that 
inflammation can also begin in the PVAT and then spread towards the artery, affecting 
the surrounding vasculature (137). The outside-in theory has been supported by evidence 
of “inflammatory cells at the junction of perivascular adipose tissue and the vascular 
adventitia," "the lack of a fascial plane between the adventitia and surrounding adipose 
tissue," and "the extension of the vasa vasorum into perivascular adipose tissue" (77, 
138).  
A limited number of studies have investigated the effects of diet on the activity 
and state of PVAT. The few studies that have investigated this have primarily employed a 
high-fat diet (HFD); in a study using female and male wild-type and AMPKα1 knock-out 
mice, the intake of a HFD led to PVAT adopting an appearance with greater similarity to 
WAT than BAT, with an increased lipid droplet size (8). The HFD was also associated 
with a significant decrease (~70%) in adiponectin content of "adipocyte-conditioned 
media from aortic PVAT” (8). Interestingly, there was no significant change in 
adiponectin gene expression identified, which suggests that a decrease in translation or 
actual secretion of adiponectin is the cause of this decreased adiponectin content 
following HFD (8). A similar study using diet-induced obese mice observed no changes 
in PVAT adiponectin mRNA expression in thoracic PVAT even after an 8-month HFD 
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(8). Therefore, further studies of this type are necessary to elucidate the association of 
adiponectin presence with HFD intake. 
While the majority of PVAT studies using diet variations have been focused upon 
a high-fat or diet-induced obese animal model, a few studies have investigated the effect 
of an improvement in diet on PVAT (11, 13, 14, 130). In a study that placed obese rats on 
a calorie-restricted diet which led to weight loss, the PVAT damage that was initially 
present in rats during obesity was reversed through a reduction in inflammation and 
increase in nitric oxide synthetase activity (130). This is evidence of the positive impact 
that dietary and lifestyle changes can have upon PVAT health. A limited number of 
studies employing functional foods (foods that confer physiological benefits) have also 
been conducted to investigate their effects on PVAT.  Studies in the Klimis-Zacas lab 
have demonstrated the efficacy of a diet enriched in wild blueberries for the attenuation 
of local obesity-induced inflammation in the PVAT (11–14). This improvement took 
place through a decrease in inflammatory marker expression, improved lipid profiles, 
normalized vascular function, and modulated oxidative stress (11–14). 
A limited number of other studies have investigated the conditions and molecules 
that prompt obesity-related changes in PVAT structure and function. In a study using 
wild-type and TNF-α receptor deficient mice (TNF-KO), the consumption of a HFD 
leading to obesity caused increased ROS generation in PVAT (126). This increased ROS 
generation was attributed to reduced mitochondrial respiration, potentially due to 
decreased UCP-1 and antioxidant expression, motivated by increased adipocyte TNF-α 
production (126). These changes are associated with further complications related to 
obesity-induced vascular dysfunction. Furthermore, it has been identified that the 
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elevated ROS generation and increased TNF-α production are associated with higher 
levels of activation of the RhoA/Rho kinase pathway in vascular smooth muscle cells 
(VSMCs) (126). Atypical activation of the RhoA/Rho kinase pathway has been 
associated with obesity-associated vascular dysfunction (126). 
 
VI. Red Raspberries 
Berries are unique in their robust antioxidant profiles, with quantities reaching 
four times that of non-berry fruits and ten times that of vegetables (139). Red raspberries 
(Rubus idaeus) are gaining recent interest due to their unique bioactive profiles (140). 
Red raspberries also possess diverse culinary applications, which make them appealing 
and adaptable to a variety of diets and lifestyles. There are around 50 different bioactive 
compounds present in red raspberries, including anthocyanins (ACNs) and ellagitannins 
(141). The ACN content of red raspberries typically ranges between 23 – 59 mg per     
100 g/FW, with cyanidin being most abundant, and lower levels of pelargonidin also 
present (139, 142).  
ACNs are a sub-class of flavonoids and are colored pigments that confer red, 
purple and blue colors to food (143). The specific color that ACNs confer is dependent 
upon their conjugation (distribution of double bonds) (143). The health benefits of ACNs 
include attenuation of inflammation, improvement of vision, prevention of cardiovascular 
diseases, and reduction of diabetes, cancer and obesity (143). Studies have demonstrated 
plant ACNs to improve lipid profiles, inhibit platelet aggregation, decrease cancer cell 
growth, improve visual function in glaucoma patients, activate adiponectin which 
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improves endothelial dysfunction, and suppress weight gain (143). Many of these health 
benefits are attributed to the antioxidant activity of ACNs.  
ACNs consist of a core flavylium ion structure, which is a flavanol derivative 
lacking a fourth-position ketone and third-position alcohol (Figure 2) (143). Different 
side chains are then attached to this core to produce varying anthocyanin identities 
(Figure 3) (143). There are two pathways used in the synthesis of ACNs: one which 
yields the two necessary precursors, and one which enables conversion to a stable form 
(139). The shikimate pathway produces the precursors phenylalanine and malonyl-CoA, 
which are then converted to unstable anthocyanidins through several folding and 
chemical steps, and are then coupled to sugars to form anthocyanins which are more 
stable (139).  
 
Figure 2: Core anthocyanin structure (143) 
 
Figure 3: Common ACN compounds in plants (143) 
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While red raspberries possess an ACN content similar to or less than that of other 
common berries, their ellagitannin content is uniquely high (144). Ellagitannins are a 
class of polyphenols that are defined by their presence of one or more 
"hexahydroxydiphenoyl moieties esterified with a sugar, usually glucose” (145). Sanguiin 
H-6 and lambertianin C are the two primary ellagitannins present in red raspberries, with 
quantities of 1871 g/mol and 2805 g/mol respectively (145). Ellagitannins have been 
documented to physiologically benefit cardiovascular health, with effects such as 
decreased atherogenesis and decreased thrombosis (146). This is due in part to the release 
of ellagic acid upon hydrolysis of ellagitannins during digestion, and thus improved 
bioavailability (146). Red raspberries are also unique in their low sugar and high fiber 
content. Compared with 1 cup of wild blueberries, 1 cup of red raspberries contains 6 
fewer grams of sugar and 1 more gram of fiber (147, 148).  
No studies have been conducted to date on the effect of red raspberries on PVAT. 
Thus, considering that wild blueberry dietary enrichment has been documented to confer 
attenuated inflammation and improved vascular function local to PVAT, it is valuable to 
elucidate the effect(s) of red raspberry dietary enrichment on PVAT. The specific goal of 
this study is to determine the effect(s) of a red raspberry-enriched diet on pro-
inflammatory and anti-inflammatory marker gene expression and concentration in the 
PVAT of the OZR model of MetS and the LZR control model. 
 
  
 
31 
 
MATERIALS AND METHODS 
 
Zucker Rats 
Sixteen male OZRs and sixteen male LZRs (Charles River laboratories, Raleigh, 
NC) were purchased in Spring 2018. The animals were housed at the University of Maine 
Small Animal Facility, individually in an environmentally-controlled room at 22°C with 
a 12-hours:12-hours light:dark cycle. Mesh-bottomed cages were used to prevent 
coprophagia. Food and water were replenished daily throughout the eight-week study. 
Weight was measured weekly using a KD-8000 scale (MyWeigh, Phoenix, AZ). 
Diets 
For eight weeks, eight OZR and eight LZR were placed on an experimental diet 
enriched with red raspberry (Rubus idaeus), and the remaining eight of each strain 
received a control diet (Dyets, Bethlehem, PA). The control diet complied with the 
requirements established in the American Institute of Nutrition’s AIN93-G rodent growth 
diet, with ingredients as indicated in Figure 4 (149). The experimental diet consisted of 
red raspberry (Rubus idaeus) powder substituted at 8% (w/w) for dyetrose in the AIN93-
G diet.  This percentage is equivalent to human consumption of approximately 1.5 cups 
of red raspberries per day, based upon the body surface area calculation (150). Diets were 
vacuum-packed and stored at -20°C in the dark prior to use. Control and experimental 
diets were distributed daily in powder form into respective glass rodent feeding jars, and 
both food and tap water were made available ab libitum.  
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Figure 4: Nutritional composition of rat control diet, based upon the American Institute of 
Nutrition’s AIN93-G rodent growth diet (149) 
 
Red Raspberries 
 Red raspberries (Rubus idaeus) were sourced, freeze-dried and powdered by 
FutureCeutricals as HiActives® Raspberry N116 Powder (Momence, Il) and processed 
into diet by Dyets (Bethlehem, PA). The red raspberry powder was analyzed by 
FutureCeutricals, indicating a 0.5% minimum total anthocyanin, 1.5% minimum total 
phenolics, 350 µmole TE/g ORAC, and 10 mg/100g Ellagic Acid. Each 100g of red 
raspberry powder contained 365 calories, 12.12 g fiber, 44.62 g sugar, and 7.92 g protein.  
Tissue Collection 
Following the eight-week experimental feeding period, two animals per day were 
anesthetized and tissue samples collected. Animals were fasted overnight but access to 
water remained. Animals were anesthetized with 95% CO2/5% O2 for two minutes, 
followed by exsanguination through cardiac puncture. The thoracic aorta was excised and 
cleaned of blood clots, and then placed in a Petri dish containing physiologic saline 
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solution (PSS: 118 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl, 1.2 mM MgSO4, 1.2 mM 
KH2PO4, 12.5 mM NaHCO3, and 11.1 mM dextrose). The PVAT were then carefully 
removed from the aorta, cleaned of blood in PSS, patted dry and weighed. It was then 
immediately placed in cryogenic vials (Thermo Scientific, Rochester, NY), snap-frozen 
in liquid nitrogen and stored at -80°C. 
PVAT Homogenate 
A PVAT homogenate was prepared using 5 mL of Phosphate-Buffered Saline 
(PBS) (Sigma-Aldrich, St. Louis, MO) and 100 mg of PVAT. PBS was filtered, and then 
chilled prior to and throughout homogenate preparation. The TissueRuptor II (Qiagen, 
Germantown, MD) with TissueRuptor Disposable Probes (Qiagen, Germantown, MD) 
were used for disruption of PVAT, for a duration of 40 seconds or until the tissue 
homogenate was uniformly homogenous. Each homogenate was then vortexed for 1 
minute, followed by centrifugation at 5,000 RPM for 10 minutes at 4 degrees C using a 
Sorvall RT1 centrifuge (ThermoScientific, Waltham, MA). The subnatant was then 
carefully collected using a glass pipette, aliquoted into microcentrifuge tubes, and stored 
at -80 degrees C until further analysis.  
Total Protein Content 
Total protein of each PVAT homogenate sample was determined using the Pierce 
BCA Protein Assay (ThermoFisher Scientific, Waltham, MA). BCA Assays were 
performed using undiluted PVAT homogenate aliquots, and according to manufacturer 
instructions. Spectrophotometric readings were determined at a wavelength of 562 nm 
using an xMark Microplate Absorbance Spectrophotometer (BioRad, CA). 
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Inflammatory Marker Concentrations 
Inflammatory marker concentrations were determined using respective ELISA 
kits. Adiponectin concentrations of PVAT homogenate samples diluted 1:50 with 
Calibrator Diluent RD5-26 (R&D Systems, Minneapolis, MN) were determined using the 
Rat Adiponectin ELISA Kit (R&D Systems, Minneapolis, MN) according to respective 
manufacturer instructions. Spectrophotometric readings were determined at a wavelength 
of 450 nm and a correction wavelength of 570 nm, using an xMark Microplate 
Absorbance Spectrophotometer (BioRad, CA). 
IL-1β concentrations of PVAT homogenate samples diluted 1:5 with 1x Sample 
Diluent (Abcam, San Francisco, CA) were determined using the Rat IL-1 beta ELISA Kit 
(Abcam, San Francisco, CA) following respective manufacturer instructions. 
Spectrophotometric readings were determined at a wavelength of 450 nm using an xMark 
Microplate Absorbance Spectrophotometer (BioRad, CA). 
IL-10 concentrations of PVAT homogenate samples diluted 1:5 with 1x Sample 
Diluent (Abcam, San Francisco, CA) were determined using the Rat IL-10 ELISA kit 
(Abcam, San Francisco, CA). Spectrophotometric readings were determined at a 
wavelength of 450 nm using an xMark Microplate Absorbance Spectrophotometer 
(BioRad, CA). 
MCP-1 concentrations of PVAT homogenate samples diluted 1:500 with Sample 
Diluent (MyBioSource, San Diego, CA) were determined using the Rat MCP-1 ELISA 
Kit (MyBioSource, San Diego, CA). Spectrophotometric readings were determined at a 
wavelength of 450 nm with a correction wavelength of 630 nm using an xMark 
Microplate Absorbance Spectrophotometer (BioRad, CA). 
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Messenger RNA Extraction from PVAT 
 Messenger RNA (mRNA) was isolated from frozen PVAT fragments using the 
RNeasy Lipid Tissue Mini-Kit (Qiagen, Germantown, MD). The TissueRuptor II 
(Qiagen, Germantown, MD) and TissueRuptor Disposable Probes (Qiagen, Germantown, 
MD) were used for processing tissue into a homogenate according to manufacturer 
instructions. RNA purity and yield (ng/µL) were determined using the Nanodrop 1000 
Spectrophotometer (Thermo Scientific, Rochester, NY). RNA yield values were used in 
the determination of total RNA volume taken per cDNA reaction, for a final 
concentration of 0.5 µg/uL. The RT2 First Strand Kit (Qiagen, Germantown, MD) was 
used for reverse transcription of RNA to cDNA, with Genomic DNA Elimination Mix 
and Reverse Transcription Mix (Qiagen, Germantown, MD). Stopped cDNA reactions 
were then stored at -80 degrees C until further use. 
Gene Expression 
Custom-designed RT2 Profiler PCR Arrays (Qiagen, Germantown, MD) were 
used for determination of NF-κB (NF-κB-1), TNF-α (TNFa), IL-6 (IL6), MCP-1 (Ccl2), 
adiponectin (adipo1), IL-10 (IL10), and IL-1β (IL1b) expression in PVAT. The 
housekeeping gene β-actin was used, and genomic DNA controls (GDC), reverse-
transcription controls (RTC), and positive PCR controls (PPC) were employed. The RT2 
Profiler PCR Array system includes the RT² First Strand Kit (Qiagen, Germantown, 
MD), Custom RT² PCR Array (Qiagen, Germantown, MD), and RT² SYBR® Green 
Mastermix (Qiagen, Germantown, MD). A Bio-Rad CFX96 Real-Time PCR Detection 
System (Bio-Rad, Hercules, CA) was used for thermal cycling and determination of Cq 
values. 
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Statistical Analysis 
Gene expression relative to the housekeeping gene beta-actin was determined with 
the ΔΔCt method, with LZR-C animals as the reference expression level (151). Data was 
analyzed using 2-way ANOVA, with the independent factors diet (red raspberry vs. 
control) and animal model (OZR vs. LZR) in the Prism application (GraphPad, San 
Diego, CA). Outliers were removed based upon the GraphPad (GraphPad, San Diego, 
CA) Outlier Calculator with an alpha value of 0.05. Tukey’s HSD post hoc test was also 
used to further determine significant main effects and interactions. 
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RESULTS 
 
Animal Weight and Food Consumption 
 Average animal weight was significantly higher during each week of the 
experimental feeding period for OZR-C animals compared with LZR-C animals (Figure 
5). No significant differences in weight were observed between diet groups compared 
with respective control models. The average final weight of LZR-C animals following the 
experimental feeding period was 434 ± 68 g, while that of OZR-C animals was 608 ±    
74 g.  
 
Figure 5: Rat growth throughout experimental duration. No significant differences in 
growth were observed in diet groups compared with control groups. +Significant 
difference in growth between LZR-C vs. OZR-C (p < 0.05), *Significant difference in 
growth between LZR-WRR vs OZR-WRR (p < 0.05) 
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Average food intake was significantly higher for OZR-C (36.29 ± 1.05 g/day) vs. 
LZR-C (26.48 ± 0.73 g/day) and OZR-WRR (35.29 ± 0.625 g/day) vs. LZR-WRR (24.38 
± 0.470 g/day) (Figure 6). No statistical significance was observed in food intake 
between control and red raspberry-enriched diets. 
 
 
Figure 6: Average food consumption for animal and diet groups. +Significant difference 
in food consumption between animal type (LZR-C vs. OZR-C, p < 0.05), *Significant 
difference in food consumption between animal types within diet group (LZR-WRR vs. 
OZR-WRR, p < 0.05) 
 
Gene Expression & Protein Concentration 
 
Adiponectin 
 Gene expression of anti-inflammatory marker adiponectin (gene name Adipoq) in 
PVAT was analyzed using RT-PCR (Figure 7), and protein concentration was determined 
using ELISA (Figure 8), as described in Methods. No significant gene expression results 
were observed either for animal type or diet. ELISA analyses indicated a significant (p < 
0.05) elevation in adiponectin concentration in OZR-WRR vs. OZR-C animals. 
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Figure 7: Gene expression of anti-inflammatory marker adiponectin in Zucker Rat PVAT 
using RT-PCR. 
 
 
Figure 8: Protein concentration of anti-inflammatory marker adiponectin in Zucker Rat 
PVAT using ELISA. 
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Interleukin-10 
Gene expression of anti-inflammatory marker IL-10 (gene name IL10) in PVAT 
was analyzed using RT-PCR (Figure 9), and protein concentration was determined using 
ELISA (Figure 10), as described in Methods. No significant gene expression results were 
observed either for animal type or diet. ELISA analyses indicated a significant (p < 0.05) 
decrease in IL-10 concentration in OZR-C versus LZR-C models. 
 
Figure 9: Gene expression of anti-inflammatory marker IL-10 in Zucker Rat PVAT using 
RT-PCR. 
 
Figure 10: Protein concentration of anti-inflammatory marker IL-10 in Zucker Rat PVAT 
using ELISA. 
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Interleukin-1β 
Gene expression of pro-inflammatory marker IL-1β (gene name IL1b) in PVAT 
was analyzed using RT-PCR (Figure 11), and protein concentration was determined using 
ELISA (Figure 12), as described in Methods. No significant gene expression changes 
were observed either for animal type or diet. ELISA analyses indicated a significant (p < 
0.05) decrease in IL-1β concentration in OZR-C versus LZR-C models.  
 
Figure 11: Gene expression of pro-inflammatory marker IL-1β in Zucker Rat PVAT 
using RT-PCR. 
 
Figure 12: Protein concentration of pro-inflammatory marker IL-1β in Zucker Rat PVAT 
using ELISA.  
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Monocyte Chemoattractant Protein-1 
Gene expression of pro-inflammatory MCP-1 (gene name Ccl2) in PVAT was 
analyzed using RT-PCR (Figure 14), and protein concentration was determined using 
ELISA (Figure 15) as described in Methods. No significant changes in gene expression 
were observed either for animal type or diet.  
 
Figure 133: Gene expression of pro-inflammatory marker MCP-1 in Zucker Rat PVAT 
using RT-PCR. 
 
Figure 14: Protein concentration of pro-inflammatory marker MCP-1 in Zucker Rat 
PVAT using ELISA. 
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Gene Expression 
 
Interleukin-6 
Gene expression of pro-inflammatory marker IL-6 (gene name IL6) in PVAT was 
analyzed using RT-PCR (Figure 13) as described in Methods. No significant changes in 
gene expression were observed either for animal type or diet. 
 
Figure 145: Gene expression of pro-inflammatory marker IL-6 in Zucker Rat PVAT 
using RT-PCR. 
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Nuclear factor-κB 
 
Gene expression of pro-inflammatory marker NF-κB (gene name Nfkb1) in PVAT 
was analyzed using RT-PCR (Figure 16) as described in Methods. A significant             
(p < 0.05) down-regulation of NF-κB in the OZR-C versus LZR-C models was found. No 
significant differences in gene expression were observed among diet groups compared to 
animal type. 
 
Figure 15: Gene expression of pro-inflammatory marker NF-κB in Zucker Rat PVAT 
using RT-PCR. 
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Tumor Necrosis Factor-Alpha 
Gene expression of pro-inflammatory marker TNF- α (gene name Tnf) in PVAT 
was analyzed using RT-PCR as described in Methods. No significant changes in gene 
expression were observed either for animal type or diet. 
 
Figure 16: Gene expression of pro-inflammatory marker TNF- α in Zucker Rat PVAT 
using RT-PCR. 
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DISCUSSION 
 
This study documents that an eight-week red raspberry dietary enrichment is 
associated with deviations in inflammatory markers in the PVAT of obese Zucker rats 
(OZR), including significantly elevated concentration of the anti-inflammatory marker 
adiponectin. This study also documents that among control (C) animals, IL-10 and IL-1β 
concentrations are both significantly higher in the PVAT of lean Zucker rats (LZR), and 
that transcription factor NF-κB expression is significantly decreased in the PVAT of 
OZR.  
Considering that adiponectin is regarded as an anti-inflammatory marker that is 
most often present in high circulating concentrations in healthy animals and individuals, 
and lower levels in cases of obesity, this finding suggests that whole-red raspberry 
(WRR) enrichment promotes a healthier outcome for the PVAT of OZR (39). As 
discussed in the literature review, adiponectin has been observed to exert protective 
effects against endothelial dysfunction, neointimal formation, and M1 polarization 
through a putative compensatory mechanism (39, 41, 44). These findings also support the 
conclusion that WRR enrichment promotes a healthier outcome for the PVAT of OZR. It 
is interesting to note that there was no significant difference in PVAT adiponectin 
expression in different diet or animal groups. This suggests that post-transcriptional 
modifications are taking place to affect the activity of adiponectin in the OZR-WRR 
animals in order to cause the observed significant difference in protein concentration. 
The documented significant elevation in concentration of anti-inflammatory 
cytokine IL-10 found in LZR-C versus OZR-C aligns with that which has been 
previously established regarding this cytokine; since it is known that IL-10 is primarily 
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produced by macrophages with M2 polarization, it is logical that LZR with lower levels 
of inflammation would possess higher levels of IL-10 (39, 48). Further, this finding 
advances the understanding of PVAT and the ways in which this organ responds to 
obesity, since no studies investigating IL-10 and PVAT were identified during this 
study’s literature review.  
Considering that IL-1β is typically viewed as a pro-inflammatory cytokine, it 
would typically be expected for it to be present at significantly higher concentrations in 
the OZR-C versus LZR-C (55). In the context of classical visceral and subcutaneous 
adipose tissue depots, cases of both rodent and human obesity have been associated with 
elevated release of IL-1β (60). Further, elevated circulating plasma levels of IL-1β are an 
established prediction of insulin resistance and subsequent development of Type 2 
Diabetes (60). However, when considering that which has been established regarding 
thoracic PVAT, the current study’s finding that IL-1β concentration is much lower in 
OZR-C PVAT than LZR-C PVAT makes more sense. Specifically, thoracic PVAT has 
been documented to benefit vascular function and exert a compensatory mechanism in 
cases of early obesity, which resists inflammation in order to maintain vascular 
homeostasis (7, 124). This is believed to be due in part to its nature as a brown adipose 
tissue (BAT), as assessed by previous studies’ immunohistochemistry, electron 
microscopy, and genetic analyses (131). 
PVAT is also unique when compared with the secretory profiles of other adipose 
tissue depots (124, 131, 132). In murine studies, aortic PVAT has been observed to 
express lower levels of adipocyte-related genes such as PPARγ, FABP4, fatty acid 
synthase (FAS), lipoprotein lipase (LPL), and perilipin, and to produce lower levels of 
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adiponectin and leptin, when compared to subcutaneous (SAT) and visceral adipose 
tissues (VAT) (124, 131, 132). This series of documented gene expression and protein 
variations provides further evidence for PVAT’s previously established unique nature. 
In this study, it seems that the OZR PVAT may be resisting inflammation by 
exerting a compensatory effect, resulting in a significantly reduced protein concentration 
of the pro-inflammatory marker IL-1β. Since thoracic PVAT has a location close to the 
heart, and surrounds the thoracic artery which all blood flows through prior to passing to 
the rest of the body, this organ may be highly important for protection and maintenance 
of a healthy, functioning homeostatic condition in cases of obesity, or at least early 
transitional stages into obesity (133).  
Further, the observed difference in IL-1β concentration is supported by the gene 
expression of NF-κB in the same animals. Specifically, in this study NF-κB mRNA was 
significantly down-regulated in the PVAT of OZR-C animals compared to LZR-C 
animals. NF-κB is a transcription factor with known functions in the activation of genes 
related to a pro-inflammatory state, with its activation occurring upon translocation to the 
nucleus from the cytoplasm, as discussed in the literature review (94, 97). The presence 
of NF-κB in the nucleus is influenced through a positive-feedback loop, with pro-
inflammatory markers (including IL-1β) acting as both enhancers and products of this 
loop, which aligns with the IL-1β concentration results observed (94).  
The NF-κB gene expression finding in this study also supports previous 
knowledge that PVAT exerts protection against inflammation (7, 124). NF-κB has been 
documented to be activated at higher levels in cases of high-fat diet feeding, and 
promotes the recruitment and activation of macrophages (94, 152). However, by reducing 
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the expression of this transcription factor, PVAT may be acting to compensate against the 
inflammatory state of the OZR-C animals, thus promoting a less-inflamed environment 
local to the heart and nearby vasculature. 
With regards to the observed modulations in PVAT inflammatory status, it is 
interesting to consider previous findings regarding the effect of PVAT on atherogenesis 
and vascular inflammation initiation (9). Specifically, it was previously believed that this 
occurred from the “inside out,” starting with injury of the intima and subsequent delivery 
of immune cells through the vasculature, which then produce inflammation that spread to 
the medial and adventitial regions of the artery wall (10). However, recent findings have 
provided evidence for a new “outside-in” theory, in which inflammation can also begin in 
the PVAT and then spread towards the artery, affecting the surrounding vasculature (10). 
With the present study’s results in mind, it seems that the elevated adiponectin 
concentration in the PVAT of OZR-WRR could be specifically conferring protection 
against atherosclerosis development. Further, the discussed suspected compensatory 
mechanism involving NF-κB and IL-1β in OZR-C vs. LZR-C rats could also have a role 
in protection against atherogenesis through an outside-in approach.  
The significant finding in this study involving elevated anti-inflammatory marker 
adiponectin concentration in PVAT of OZR in cases of red raspberry enrichment suggests 
that the nutrient and bioactive profiles of this berry may enhance adiponectin’s role in the 
discussed compensatory mechanism of action. Red raspberries possess a diversity of 
different bioactive compounds, including anthocyanins (ACNs) and ellagitannins (141). 
Plant ACNs have been documented to confer many benefits, and adiponectin activation is 
notably one of these (143). Also relevant is evidence that ACNs improve lipid profiles 
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and endothelial function, and suppress weight gain, and that ellagitannins confer 
cardiovascular benefits and protection (10, 143).  
It is also valuable to compare findings with the limited published research that 
exists regarding the effect of berry consumption on PVAT. A previous study in the 
Klimis-Zacas laboratory demonstrated the efficacy of a wild blueberry-enriched (WBB) 
diet in the attenuation of obesity-induced inflammation, through significantly decreasing 
expression of inflammatory markers in the PVAT of the same Zucker rat models 
employed in the present study (11). Significant results from the WBB study included 
decreased PVAT concentrations of pro-inflammatory markers MCP-1 and TNF-α in OZR 
that consumed WBB, as well as decreased concentrations of the same pro-inflammatory 
markers in the PVAT of LZR-C vs. OZR-C animals (11).  
In the present study there was not a significant difference in MCP-1 concentration 
in any case, with p-values of 0.6258 (OZR-C vs. OZR-WRR) and 0.9204 (LZR-C vs. 
OZR-C). It is also important to note that in the present study TNF-α concentration via 
ELISA analysis was attempted using several different concentrations of PVAT 
homogenate, and both with and without protease inhibitors, however in every case TNF-α 
was not present at spectrophotometrically detectable levels. Variations in inflammatory 
marker concentration may be due to differences in the bioactive profile of WBB 
compared to WRR. The total phenolic content and total antioxidant capacity of WRR are 
both lower than that of WBB, at a quantity of four-fold and three-fold less, respectively 
(153). Further, WBB possess a bioactive profile with much greater diversity than that of 
WRR; these variations in both bioactive type and concentration can translate to varying 
physiological effects (154).  
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In a study that investigated the antioxidant capacity of varying berries, it was 
determined that WRR (Rubus idaeus Michx) contained 7.1 µmol of gallic acid/g FW, 
0.84 µmol of the anthocyanin Mal-3-glu/g FW, and 21.4 µmol of peroxyl radical 
absorbance capacity (ORAC-ROO)/g FW (155). This is compared with WBB (Vaccinium 
angustifolium Aiton), with 27.7 µmol of gallic acid/g FW, 4.35 µmol of the anthocyanin 
Mal-3-glu/g FW, and 64.4 µmol of ORAC-ROO/g FW (155). Further, analysis of a WRR 
extract bioactive profile determined that the compounds sanguiin H-10 (an ellagitannin), 
lambertianin C (an ellagitannin component), quercetin-3,4'-diglucoside, sanguiin H-6 (an 
ellagitannin), and ellagic acid to are present at the highest concentrations (156). Ellagic 
acid is a product of ellagitannin hydrolysis during digestion, and ellagitannins have been 
documented to physiologically benefit cardiovascular health, with effects such as 
decreased atherogenesis and decreased thrombosis (146). No studies that evaluated 
specific health benefits of quercetin-3,4'-diglucoside have been identified, however 
considering its antioxidant activity it is suspected that it likely exerts beneficial 
physiological effects (157).  
The WRR bioactive profile is contrasted with that of WBB, which contains high 
levels of the compounds chlorogenic acid, quercetin and resveratrol, as well as over 
twenty different anthocyanidins (including delphinidin, malvidin, cyanidin, petunidin and 
peonidin in greatest abundance) (158). These anthocyanidins then become anthocyanins 
upon combining with glucose, galactose and arabinose to form anthocyanins such as 3-
glucoside, 3-galactoside and 3-arabinoside (154). WBB also possess the flavonoids 
flavan and flavonol (159). These compounds can have a unique effect when acting in 
synergy together, which is another variable that is different when comparing WRR to 
 
52 
 
WBB due to the diverse bioactive profile of WBB (160). With these documented 
phenolic compound contents in mind, it is important to note that factors such as 
environmental and harvest conditions, and treatment and storage following harvest, can 
have an effect on berry phenolic content greatly (158). 
In conclusion, the present study provides evidence that consumption of WRR at a 
human-equivalent rate of 1.5 cups per day can improve the response of anti-inflammatory 
marker adiponectin to obesity-induced inflammation local to PVAT, through a 
compensatory mechanism, however this is with an effect lower than that of previous 
WBB studies. The present study also provides evidence for the role of transcription factor 
NF-κB subunit p50 in a PVAT-based anti-inflammatory compensatory mechanism in 
cases of early obesity, in concert with pro-inflammatory cytokine IL-1β. These findings 
support previous data that have identified thoracic PVAT as a BAT that confers 
protection against inflammation, as well as prior evidence that berries can be an effective 
non-pharmacological tool for the attenuation of MetS and obesity-induced inflammation. 
 
 
 
 
 
  
 
53 
 
FUTURE DIRECTIONS 
 
 This study investigated the effects of whole red-raspberry (WRR) consumption in 
the perivascular adipose tissue (PVAT) of the obese Zucker rat model (OZR) of human 
Metabolic Syndrome (MetS), and also employed control lean (LZR-C) and obese (OZR-
C) models. The WRR consumption was equivalent to human consumption of 
approximately 1.5 cups of fresh WRR per day. The age of the rats at arrival was eight 
weeks, and the experimental feeding period took place for a duration of eight weeks. 
PVAT was collected and subsequent experiments investigated the gene expression and 
protein concentrations of seven key pro- and anti-inflammatory markers. 
 Studies were not conducted to directly investigate the adipocyte phenotype of the 
PVAT. Previous published research has determined that murine thoracic PVAT most 
resembles brown adipose tissue (BAT) or beige adipose tissue, with BAT generally 
associated with a healthier phenotype due to its resistance to inflammation and higher 
expenditure of energy (125, 131, 161). Therefore, investigating the differential histology 
of OZR-C versus LZR-C and OZR-C versus OZR-WRR PVAT could provide insight to 
obesity- and WRR-enrichment-related differences in adipocyte structure and function. 
The phenotypes of these samples could be investigated through direct tissue histology 
sample analyses, as well as genetic and proteomic investigations of UCP-1 content (162). 
 Other studies that could provide valuable insight to the PVAT inflammatory state 
involve the transcription factor NF-κB. As discussed in the literature review, while      
NF-κB consists of five possible subunits (and most often just the subunits p50 and p65), 
this study only investigated the mRNA expression of the p50 subunit (95). While this 
does provide insight to the presence and functioning of NF-κB, a greater understanding 
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could be created through also determining gene expression of the other four subunits, or 
at least p65. A related study could investigate levels of IKBα, a key inhibitor of NF-κB’s 
translocation into the nucleus, to elucidate differential regulation of this transcription 
factor’s pathway (and subsequent ability to act upon its target genes, including those 
which were investigated in this study) (97).  
Other upstream molecules of NF-κB that could be valuable to investigate are toll-
like receptor ligands and cytokines, which can induce the first signaling for NLRP3 
inflammasome activation (163). These cytokines include IL-1β that was investigated in 
this study, as well as TNF-α that was attempted to be investigated; however other 
molecules that can induce NLRP3 inflammasome activity are pathogen-associated 
molecular pattern molecules (PAMPs) and damage-associated molecular pattern 
molecules (DAMPs) (163). It could also be insightful to investigate the gene expression 
and activity of a greater range of NF-κB pathway components, such as those involved in 
signaling [such as thrombin receptor (F2r) and toll-like receptor 1 (tlr1)], sequestration of 
NF-κB for control of activity [such as NFKB inhibitor alpha (Nfkbia) and component of 
inhibitor of nuclear factor kappa B kinase complex (chuk)], and downstream targets of 
NF-κB [such as mitogen activated protein kinase 3 (mapk3) and TNF receptor associated 
factors (TRAFs)] (164, 165). 
 Future studies should also examine the cross-talk between PVAT brown versus 
visceral white adipose tissue inflammation. Considering that PVAT is a highly-active 
endocrine organ with the ability to communicate with remote adipose depots, questions 
remain regarding how these other depots are affected by both MetS and WRR 
consumption (7). Questions also remain regarding the effect of rodent age on PVAT 
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response to red raspberry dietary enrichment. At the age of 8-16 weeks the consequences 
of MetS are still developing, so it would be valuable to gain data regarding the effect of 
WRR consumption on rats who have experienced a more extended duration of 
inflammation (158). This would help to inform nutritional recommendations for patients 
of varying age and MetS progression status. 
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APPENDIX 
 
IACUC Approval 
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